Ketamine therapy has a perception problem. Not among the psychiatrists who prescribe it or the patients who have experienced its effects firsthand, but among the broader public and even among some clinicians who have not followed the research closely.
The perception goes something like this: ketamine works fast but does not last. It is a short-term fix, a reset button that fades within days or weeks. For patients dealing with serious, long-term depression, the implication is that ketamine offers temporary relief but not a durable solution.
This perception is worth examining carefully, because the research tells a more nuanced and considerably more encouraging story than the short-term fix narrative suggests.
What We Know About Ketamine’s Acute Effects
Let us start with what is not in dispute. A single ketamine infusion produces a rapid antidepressant effect that typically peaks within 24 to 72 hours and then diminishes over the following one to two weeks in most patients. This is well-established across dozens of clinical trials and is one of ketamine’s defining characteristics.
The rapid onset is what makes ketamine uniquely valuable for patients in acute crisis, particularly those with active suicidal ideation, where waiting weeks for an SSRI to take effect is not a viable option. But the two-week window of a single infusion is also why the short-term fix narrative gained traction in the first place.
The problem with that narrative is that it treats a single infusion as the full treatment, which it is not.
What a Full Course of Ketamine Actually Looks Like
The standard ketamine protocol for depression is not one infusion. It is a series of six infusions delivered over two to three weeks, followed by maintenance infusions as needed. The research on outcomes from a full course of treatment tells a significantly different story than the single-infusion literature.
A 2021 meta-analysis published in the Journal of Affective Disorders analyzed outcomes from multiple ketamine treatment studies and found that response rates after a full course of infusions were substantially higher and more durable than those seen after a single infusion. Patients who completed a full course and maintained a response were more likely to sustain that response over subsequent months than the single-infusion data would suggest.
A 2022 study published in the American Journal of Psychiatry followed patients who had responded to a course of ketamine infusions and received maintenance infusions over a six-month period. The study found that maintenance ketamine was associated with sustained antidepressant effects, with a significant proportion of patients maintaining response or remission throughout the follow-up period.
A single ketamine infusion typically produces antidepressant effects that peak within 24 to 72 hours and diminish over one to two weeks. A full course of six infusions produces significantly more durable effects, with many patients maintaining improvement for months, particularly when supported by maintenance infusions and complementary treatments.
No. The short-term fix narrative is based on single-infusion data, which is not how ketamine is clinically administered for depression. A full course of infusions followed by maintenance treatment produces durable antidepressant effects that are clinically meaningful over months to years for many patients.
The standard protocol is six infusions delivered over two to three weeks, followed by maintenance infusions as needed. Completing the full initial course is associated with better and more durable outcomes than stopping after one or two infusions.
Yes. Patients who combine ketamine with therapy, TMS, or optimized medication management tend to have more durable outcomes than those using ketamine as a standalone treatment. The neuroplastic window that ketamine opens makes the brain particularly receptive to complementary interventions.
The Neuroplasticity Mechanism and Why It Matters for Durability
Understanding why ketamine can produce durable effects requires understanding what it does to the brain beyond its immediate pharmacological action.
Ketamine’s antidepressant effect is initiated by its blockade of NMDA receptors and the resulting surge in glutamate signaling. But what follows that initial surge is what produces lasting change. The glutamate surge triggers the release of brain-derived neurotrophic factor, or BDNF, a protein that promotes the growth of new synaptic connections in the prefrontal cortex and hippocampus, areas of the brain that are structurally compromised in chronic depression.
In other words, ketamine does not just change how the brain feels in the short term. It initiates a process of structural repair that, when supported by a full treatment course and appropriate follow-up care, can produce changes that outlast the drug’s presence in the system by weeks, months, or longer.
This neuroplastic mechanism is why the therapeutic window immediately following a ketamine infusion, the period when BDNF levels are elevated and new synaptic connections are forming, is considered particularly valuable for integrating therapy, behavioral change, and other supportive interventions. The brain is literally more receptive to learning and change during this window.
The Role of Maintenance Infusions
The most honest framing of ketamine’s long-term effectiveness is this: for many patients, it requires ongoing management, just like most other treatments for a chronic condition.
Patients with hypertension take medication indefinitely. Patients with diabetes manage their condition continuously. Depression, for many people, is similarly a chronic condition that requires ongoing care rather than a one-time cure. The relevant question is not whether ketamine lasts forever after a single course, but whether it provides durable, manageable relief as part of an ongoing treatment strategy.
The evidence on maintenance ketamine is encouraging. A 2023 randomized controlled trial published in the New England Journal of Medicine compared maintenance ketamine to placebo in patients who had responded to an initial course of infusions. Patients receiving maintenance ketamine had significantly longer time to relapse than those receiving placebo, with a median time to relapse of 19 weeks in the maintenance group compared to 6 weeks in the placebo group.
That is a clinically meaningful difference. And for patients who integrate maintenance ketamine into a broader treatment plan that also includes TMS, therapy, or GeneSight-optimized medication management, the durability picture is more favorable still.
Ketamine Compared to Other Treatments for Durability
It is also worth putting ketamine’s durability in context by comparing it to the alternatives.
Antidepressants, the standard first-line treatment for depression, require continuous daily dosing to maintain their effect. Stopping an antidepressant typically results in return of symptoms within weeks to months for most patients. The durability of antidepressants is entirely dependent on continued use.
ECT, the most effective treatment for severe depression, has a well-documented high relapse rate. A landmark study found that without maintenance treatment, more than 80 percent of patients who responded to ECT relapsed within six months. Maintenance ECT and continuation antidepressant therapy are both required to sustain ECT’s benefits.
TMS, like ketamine, produces results that are durable for many patients after a full course, with many patients maintaining improvement for a year or more. Some patients require maintenance TMS sessions when symptoms begin to return.
In this context, ketamine’s durability profile is not uniquely weak. It is consistent with the reality of depression as a chronic condition that requires ongoing management for many patients.
What Affects How Long Ketamine’s Effects Last?
Several factors influence how durable a patient’s ketamine response is:
Completing a full course. Patients who complete all six infusions in the initial course have better and more durable outcomes than those who stop after one or two infusions based on the initial response.
Integration with other treatments. Patients who combine ketamine with therapy, TMS, or optimized medication management tend to have more durable outcomes than those who use ketamine as a standalone treatment.
Maintenance infusions. Proactively scheduling maintenance infusions when symptoms begin to return extends the duration of benefit significantly compared to waiting for a full relapse.
Lifestyle factors. Sleep, exercise, stress management, and social support all influence the durability of ketamine’s effects. The neuroplastic window that ketamine opens is an opportunity to build and reinforce healthy patterns that support long-term mental health.
Individual biology. Some patients maintain robust responses for many months after a course of ketamine without maintenance. Others require more frequent support. Individual variation is real and should be planned for rather than ignored.
The Bottom Line on Ketamine’s Long-Term Effectiveness
The research does not support the narrative that ketamine is simply a short-term fix. What the research actually shows is that ketamine, when delivered as a full course and supported by maintenance infusions and complementary treatments, produces durable antidepressant effects that are clinically meaningful over months to years for many patients.
It is not a cure. It is a powerful treatment for a chronic condition that, like most treatments for chronic conditions, works best when it is part of an ongoing, thoughtfully managed care plan.
For patients who have been told that ketamine only lasts a few weeks, or who have hesitated to pursue it because they were concerned the effects would not last, the evidence is more encouraging than that framing suggests.
| Ketamine Therapy at NeuPath Mind Wellness |
|---|
| At NeuPath Mind Wellness, we approach ketamine therapy as part of a comprehensive, long-term treatment relationship rather than a series of isolated infusions. Our psychiatrists monitor your response over time, adjust your maintenance schedule based on your individual pattern, and coordinate your ketamine care with TMS, Spravato, GeneSight testing, and medication management as appropriate. We offer ketamine therapy across all three of our South Florida locations in Delray Beach, Boca Raton, and Boynton Beach. Free consultations are available at all three locations. |
| Book your free consultation today. |
